PRIVILEGED & CONFIDENTIAL ATTORNEY-CLIENT COMMUNICATION ATTORNEY WORK PRODUCT
CALDERWOOD & HARKNESS LLP
TAX DEPARTMENT
MEMORANDUM
FROM: Leonard Cross, Responsible Partner, Tax Department Sylvia Hartwell, Billing Partner, Tax Department Calderwood & Harkness LLP
TO: Marcus Whitfield, Vice President, Global Tax, Penterra Pharmaceuticals Corp. Deborah Staines, General Counsel, Penterra Pharmaceuticals Corp. Rajesh Iyer, Chief Financial Officer, Penterra Pharmaceuticals Corp.
DATE: March 18, 2024
RE: Analysis of IRS Appeals Settlement Offer — Proposed $47.6 Million Adjustment (Tax Years 2017–2020); IRS Exam Team ID LB&I-NE-TP-2022-00641; C&H Matter No. 1018-00009
CC: Garrett Simmons, Lead Associate, Calderwood & Harkness LLP Leila Nazari, Working Associate, Calderwood & Harkness LLP
This memorandum is a privileged and confidential attorney-client communication and constitutes attorney work product prepared in anticipation of litigation. It is intended solely for the use of the named recipients and should not be disclosed, distributed, or reproduced without the prior written consent of Calderwood & Harkness LLP. Unauthorized disclosure may result in waiver of the attorney-client privilege and/or work-product protection.
Right-click to update Table of Contents
I. Executive Summary
On March 15, 2024, IRS Appeals Officer Noreen Castañeda issued a formal settlement offer to resolve the Internal Revenue Service's proposed transfer pricing adjustments for tax years 2017 through 2020, arising from the examination of Penterra Pharmaceuticals Corp. ("PPC" or the "Company"). The settlement offer follows the in-person Appeals conference held on February 28, 2024, at the IRS Appeals Office in Manhattan, and PPC's supplemental submission filed on March 8, 2024.
The settlement proposes a total income adjustment of $47,600,000 across all four tax years under examination. This figure represents 12.51% of the IRS examination team's net proposed adjustment of $380,400,000 — a reduction of $332,800,000 from the amounts originally proposed in the Notice of Proposed Adjustment ("NOPA") issued October 12, 2023. The settlement further provides for the full abatement of the proposed IRC § 6662(e) substantial valuation misstatement penalty of $15,977,000.
The estimated total cash cost to PPC under the settlement is approximately $12,840,000, consisting of approximately $10,000,000 in federal income tax (computed at the 21% corporate rate on the $47,600,000 adjustment) and an estimated $2,840,000 in underpayment interest. This total represents an approximately 86.6% reduction from the total proposed tax-plus-penalty exposure of approximately $95,860,000 that PPC would have faced had the IRS's full proposed adjustments been sustained.
After thorough analysis of the settlement terms, the underlying factual and legal positions of the parties, the hazards of litigation, the financial reporting implications, and the collateral consequences for PPC's credit facility and SEC disclosure obligations, Calderwood & Harkness recommends that PPC accept the settlement offer. The settlement falls squarely within the target range of 10–15% of proposed adjustments that Calderwood & Harkness identified as a realistic and favorable outcome prior to the Appeals conference, and well within the hard ceiling of 20% that PPC management authorized for settlement discussions.
We recommend that PPC provide its formal acceptance no later than March 25, 2024, to facilitate the prompt negotiation and execution of the Form 906 Closing Agreement with the IRS, which we anticipate completing by the end of March 2024. This memorandum sets forth the detailed analysis supporting our recommendation and outlines the steps necessary to finalize the settlement and address related tax, financial reporting, credit facility, and disclosure matters.
II. Background: The IRS Examination and Proposed Adjustments
A. Examination History
The IRS Large Business & International Division ("LB&I") opened an examination of PPC on May 16, 2022, as evidenced by Letter 2205-A (Notification of Examination). The examination was assigned Exam Team ID LB&I-NE-TP-2022-00641 and covered PPC's federal income tax returns (Forms 1120) for the following tax years:
• Tax Year 2017
• Tax Year 2018
• Tax Year 2019
• Tax Year 2020
PPC's Employer Identification Number is 22-3741856. The examination was conducted out of the LB&I Northeast Transfer Pricing Practice Area, reflecting the specialized nature of the issues under review.
From its inception, the examination focused on PPC's transfer pricing methodology for intercompany transactions with its Irish IP-holding subsidiary, Penterra Biopharma International DAC ("PBI"), a designated activity company organized under the laws of Ireland and tax-resident in Ireland. The two principal intercompany arrangements under scrutiny were: (i) a qualified cost-sharing arrangement ("CSA") between PPC and PBI, effective July 1, 2012, under which the parties shared intangible development costs in proportion to their reasonably anticipated benefits from the resulting intangible property, and (ii) a legacy intellectual property royalty arrangement under which PBI paid PPC a royalty of 4.5% of net sales on pre-CSA intangible property licensed to PBI for exploitation in non-Americas territories.
The IRS examining team was composed of the following individuals:
• Supervisory Revenue Agent Gerald Meskill — Team Manager
• Lead Revenue Agent Patricia Dunleavy — Primary examiner
• Dr. Alan Washburne — IRS Economist, Office of Chief Counsel Transfer Pricing Practice
• Franklin Rosario — Attorney-Advisor, IRS Office of Chief Counsel
Over the course of the examination, the IRS issued a total of forty-seven (47) Information Document Requests ("IDRs") between June 2022 and September 2023. These IDRs encompassed a broad range of materials, including PPC's contemporaneous transfer pricing documentation, economic analyses, CSA cost-pool computations, benefit-sharing calculations, intercompany agreements, board minutes and corporate governance records for both PPC and PBI, PBI employee records and organizational charts, financial statements, R&D expenditure records, regulatory filings, market data, and internal management presentations relating to the transfer pricing policies at issue.
PPC engaged Calderwood & Harkness LLP on June 2, 2022, promptly following receipt of the Letter 2205-A, to serve as tax controversy counsel for the examination. Calderwood & Harkness subsequently retained Whitmore Valuation Group LLC ("Whitmore") under a Kovel arrangement on June 20, 2022, to provide economic and valuation expertise in connection with the defense of PPC's transfer pricing positions. Dr. Helena Vasquez of Whitmore served as the lead expert throughout the engagement.
B. The Notice of Proposed Adjustment (NOPA) — October 12, 2023
On October 12, 2023, the IRS examination team issued its Notice of Proposed Adjustment ("NOPA") for all four tax years under examination. The NOPA set forth the IRS's proposed income adjustments and the legal and economic bases for those adjustments. This was followed by the issuance of the 30-Day Letter on November 8, 2023, which formally notified PPC of its right to file a written protest and request consideration by the IRS Independent Office of Appeals.
In the NOPA, the IRS asserted four primary positions challenging PPC's transfer pricing arrangements with PBI:
1. CSA Cost-Sharing Ratio Adjustment. The IRS proposed increasing PBI's cost-sharing percentage under the CSA by 8 to 12 percentage points per year for each of the four tax years under examination. The IRS's position was that PPC's reasonably anticipated benefit ("RAB") projections, which were used to determine the cost-sharing ratios under the CSA, systematically understated the value attributable to U.S.-source contributions and, correspondingly, overstated the portion of benefits anticipated to be derived by PBI from the jointly developed intangible property. The IRS asserted that PPC's RAB methodology failed to adequately capture the value of certain U.S.-based research capabilities, clinical trial infrastructure, and regulatory expertise that the IRS contended contributed disproportionately to the overall value of the developed intangibles.
2. Legacy IP Royalty Rate Adjustment. The IRS proposed increasing the royalty rate applicable to PBI's use of pre-CSA intellectual property from the contractual rate of 4.5% of net sales to 11.0% of net sales. The IRS based this proposed increase on its own selection of comparable uncontrolled transactions ("CUTs"), which the IRS contended demonstrated that the arm's-length royalty rate for the licensed pharmaceutical intangible property was substantially higher than the rate charged by PPC.
3. Platform Contribution Transaction ("PCT") Undervaluation. Although the PCT payment was made in connection with the formation of the CSA in 2012 — a year outside the examination period — the IRS used its own valuation of the PCT as a basis for supporting its adjustments to income in the 2017–2020 tax years. Specifically, the IRS valued the PCT at $852 million, compared to PPC's original PCT valuation of $312 million. The IRS contended that the understated PCT value indicated that PPC had transferred excessive value to PBI at the outset of the CSA, which in turn supported the view that PPC's cost-sharing ratios and royalty rates were set at non-arm's-length levels during the examination period.
4. Economic Substance Challenge. The IRS asserted that PBI lacked sufficient economic substance to be respected as the beneficial owner of the intangible property and commercial rights at issue, and that key Development, Enhancement, Maintenance, Protection, and Exploitation ("DEMPE") functions remained in the United States. If sustained, this position would have had the effect of recharacterizing substantial portions of PBI's income as U.S.-source income attributable to PPC.
C. Summary of Proposed Adjustments
The NOPA set forth the following specific proposed adjustments, organized by issue and by tax year:
CSA Cost-Sharing Adjustments (Proposed Additional Payments to PPC)
The IRS's proposed CSA adjustments aggregated to $235,010,000 over the four-year examination period, reflecting the IRS's position that PBI's cost-sharing payments to PPC should have been substantially higher in each year.
Legacy IP Royalty Adjustments (Increase from 4.5% to 11.0%)
The decline in PBI net sales over the period reflects the gradual transition of legacy products to the CSA regime and the impact of generic competition on certain legacy pharmaceutical products.
Net Proposed Adjustment
The IRS examination team allowed a correlative offset of ($42,650,000) to avoid double-counting income between the CSA and royalty adjustments, where both adjustments applied to overlapping income streams. After this offset, the net proposed adjustment was computed as follows:
Proposed Penalties. The IRS proposed the application of the IRC § 6662(e) substantial valuation misstatement penalty at the rate of 20%, computed as follows:
$380,400,000 (net proposed adjustment) × 21% (corporate tax rate) × 20% (penalty rate) = $15,977,000
Total Proposed Tax and Penalty Exposure
This total represents PPC's maximum pre-interest exposure had the IRS's proposed adjustments been sustained in full.
D. The Formal Protest
PPC, through Calderwood & Harkness, filed its Formal Protest with the IRS on December 22, 2023, within the extended deadline negotiated with the examination team. The Protest contested all four of the IRS's primary positions set forth in the NOPA, advancing both factual and legal arguments on each issue. The Protest was accompanied by five substantive exhibits:
Exhibit 1: PPC and PBI Corporate Structure and Organizational Chart, demonstrating the independent operational structure of PBI, including its Irish management team, board composition, and functional departments.
Exhibit 2: CSA Summary and Cost-Sharing Computations, including detailed RAB analyses for each tax year, with supporting revenue projections, product-level forecasts, and allocation methodologies.
Exhibit 3: Whitmore Valuation Group Economic Analyses, comprising a comprehensive comparable profits method ("CPM") / transactional net margin method ("TNMM") benchmarking study, CUT analysis for the royalty rate, and a discounted cash flow ("DCF") valuation of the PCT.
Exhibit 4: PBI Economic Substance Evidence, including employee headcount data, office lease and facilities documentation, regulatory expenditure records, board meeting minutes, and summaries of key PBI employee interviews conducted by Calderwood & Harkness.
Exhibit 5: Penalty Protection Documentation, consisting of PPC's contemporaneous transfer pricing documentation prepared by Crestfield & Associates LLP under IRC § 6662(e)(3)(B) standards, as well as a summary of PPC's reasonable reliance on qualified advisors.
The case was assigned to IRS Appeals Officer Noreen Castañeda in January 2024.
E. The Appeals Conference — February 28, 2024
An in-person Appeals conference was held on February 28, 2024, at the IRS Appeals Office in Manhattan. The following individuals attended:
On behalf of PPC:
• Leonard Cross, Partner, Calderwood & Harkness LLP
• Sylvia Hartwell, Partner, Calderwood & Harkness LLP
• Garrett Simmons, Associate, Calderwood & Harkness LLP
• Marcus Whitfield, Vice President, Global Tax, PPC
• Deborah Staines, General Counsel, PPC
• Dr. Helena Vasquez, Managing Director, Whitmore Valuation Group LLC
On behalf of the IRS:
• Noreen Castañeda, Appeals Officer, IRS Independent Office of Appeals
The conference lasted approximately five hours and covered all four issues raised in the NOPA. Appeals Officer Castañeda engaged substantively with the economic analyses and posed detailed questions regarding PPC's RAB methodology, the comparability of PPC's selected CUTs, PBI's functional profile and risk-bearing capacity, and the basis for PPC's PCT valuation. During the conference, Appeals Officer Castañeda requested additional comparable uncontrolled transaction data and updated benchmarking information to supplement the materials already on file.
In response to that request, Calderwood & Harkness filed a supplemental submission on March 8, 2024, providing six additional CUT comparables identified by Whitmore, together with updated benchmarking data for the 2019 and 2020 tax years that had not been available at the time of the original Protest filing. The supplemental submission was accompanied by a detailed memorandum from Dr. Vasquez explaining the comparability adjustments applied to the newly identified CUTs and their implications for the arm's-length range.
The formal settlement offer from Appeals Officer Castañeda followed on March 15, 2024, seven days after receipt of the supplemental submission.
III. Terms of the Settlement Offer
The following sets forth the material terms of the settlement offer communicated by Appeals Officer Castañeda on March 15, 2024. The offer was conveyed orally to Leonard Cross and Garrett Simmons and confirmed in a written settlement memorandum transmitted by facsimile to Calderwood & Harkness on the same date.
A. Total Adjustment Amount
The settlement proposes a total income adjustment of $47,600,000 across all four tax years under examination. This figure represents 12.51% of the IRS examination team's net proposed adjustment of $380,400,000. The adjustment represents a compromise resolution of all transfer pricing issues raised in the NOPA, including the CSA cost-sharing adjustments, the legacy IP royalty rate adjustment, the PCT valuation dispute, and the economic substance challenge.
B. Year-by-Year Allocation
The settlement adjustment is allocated across the four tax years as follows:
It is important to note that the year-by-year allocation reflects a blended resolution that does not separately attribute amounts to the CSA cost-sharing issue versus the legacy IP royalty issue. This approach is consistent with standard IRS Appeals practice of resolving all issues on a global basis, rather than bifurcating the settlement into issue-by-issue concessions. The allocation across years was designed by Appeals to achieve a reasonable proportional distribution that takes into account the relative magnitude of the proposed adjustments in each year and the varying strength of the IRS's position across the examination period.
C. Penalty Abatement
The settlement provides for the full abatement of the proposed IRC § 6662(e) substantial valuation misstatement penalty. The IRS examination team had proposed this penalty at the 20% rate, which would have resulted in a penalty of $15,977,000 on the full $380,400,000 proposed adjustment.
Appeals Officer Castañeda accepted PPC's reasonable-cause defense, which was grounded in the contemporaneous transfer pricing documentation prepared by Crestfield & Associates LLP (Susan Lam, Transfer Pricing Partner) under the standards of IRC § 6662(e)(3)(B). The penalty-protection documentation was prepared at the time each relevant tax return was filed, and it documented PPC's selection and application of the transfer pricing methods used for its intercompany transactions with PBI. Appeals determined that PPC's documentation met the threshold requirements for the reasonable-cause exception and that PPC had demonstrated a good-faith effort to determine the correct transfer price.
Additionally, it should be noted that the IRS examination team had reserved the right to assert, but had not formally asserted, the IRC § 6662(h) gross valuation misstatement penalty at the 40% rate. The settlement resolves this reserved issue as well, eliminating any risk that a gross valuation misstatement penalty could be asserted for the 2017–2020 tax years.
The total penalty savings achieved through the settlement is $15,977,000. This figure represents the penalty amount that would have applied to the full proposed adjustment; the penalty savings associated with the settlement's reduction of the underlying income adjustment are reflected in the overall economic analysis set forth in Section IV below.
D. Closing Mechanism
The settlement will be memorialized in a Form 906 Closing Agreement under IRC § 7121. The Form 906 is a formal, written agreement between the taxpayer and the IRS that is binding on both parties with respect to the specific tax matters covered by the agreement. The principal terms of the closing mechanism are as follows:
(i) The Closing Agreement will be binding on both PPC and the IRS for Tax Years 2017, 2018, 2019, and 2020 with respect to all transfer pricing issues arising from the intercompany transactions between PPC and PBI that were the subject of the examination.
(ii) The Closing Agreement does not bind PPC or the IRS with respect to subsequent tax years. The IRS retains the right to examine PPC's transfer pricing for tax years 2021 and forward, and PPC retains the right to defend its positions for those years on the merits, unconstrained by the settlement terms.
(iii) Following execution of the Closing Agreement, PPC will be required to file amended federal income tax returns (Forms 1120X) for Tax Years 2017 through 2020, reflecting the agreed-upon income adjustments.
(iv) PPC will remit the tax and interest due upon the IRS's issuance of formal assessments following execution of the Closing Agreement. The precise interest amounts will be computed by the IRS based on the applicable federal underpayment rate for each quarter from the original due date of each return through the date of payment.
Calderwood & Harkness will prepare the initial draft of the Form 906 Closing Agreement for negotiation with Appeals Officer Castañeda. Based on our prior experience with Form 906 negotiations in comparable matters, we anticipate that the drafting and execution process can be completed within approximately two to three weeks following PPC's formal acceptance of the settlement terms.
IV. Financial Impact Analysis
This section quantifies the financial impact of the proposed settlement on PPC, including federal tax liability, interest, total cash cost, professional fees, and a comparison to the full proposed adjustment.
A. Federal Tax Liability
The federal income tax liability arising from the settlement is computed as follows:
Settlement income adjustment: $47,600,000
Applicable corporate tax rate: 21%
Tax due: $47,600,000 × 21% = $9,996,000, rounded to $10,000,000
We note that Tax Year 2017 was partially subject to the pre-Tax Cuts and Jobs Act ("TCJA") corporate tax rate of 35%. However, the settlement allocation and the IRS's computation applies the blended post-TCJA rate for computational simplicity in this context. PPC's fiscal year 2017 return applied a blended rate as required under the TCJA transition provisions, but the 21% rate is the operative rate used in the settlement calculations as agreed between the parties. Any minor variance attributable to the blended rate computation will be resolved in the final amended return computations.
B. Interest on Underpayment
Calderwood & Harkness estimates underpayment interest of approximately $2,840,000 across all four tax years. This estimate is computed at the applicable federal underpayment rate — defined as the short-term applicable federal rate ("AFR") plus three percentage points — for each calendar quarter from the original due date of each return through the anticipated payment date, which we project to be in or around May 2024.
Interest on underpayments of federal income tax is non-deductible for federal income tax purposes under IRC § 163(k). This means that the interest cost represents a true economic cost to PPC that cannot be offset through a tax deduction.
The final interest amount will be computed by the IRS upon formal assessment of the additional tax following execution of the Closing Agreement. Our estimate of $2,840,000 is based on published AFR tables and assumes a payment date of approximately May 15, 2024. The actual amount may vary modestly depending on the precise date of assessment and payment.
C. Total Cash Cost
The total estimated cash cost to PPC under the settlement is summarized below:
D. Professional Fees Incurred (for Context)
While professional fees are sunk costs and are not directly affected by the settlement decision, they are relevant context for evaluating the total cost of the examination to PPC. The professional fees incurred in connection with the examination and Appeals process are set forth below:
The Calderwood & Harkness fees include all time incurred by attorneys and paraprofessionals from the commencement of the engagement on June 2, 2022, through the anticipated close of the matter, including the preparation and negotiation of the Closing Agreement and amended return filing instructions. The Whitmore Valuation Group fees reflect the cost of the economic analyses, benchmarking studies, CUT analyses, and DCF valuation work performed throughout the engagement, including the supplemental analyses prepared for the Appeals conference and the March 8, 2024 supplemental submission. The Thornbury & Keogh fees reflect coordination with Irish tax counsel regarding the cross-border implications of the examination and the settlement.
E. Total Cost of Examination to PPC
Combining the settlement-related cash costs with the professional fees incurred, the total cost of the examination to PPC is estimated as follows:
F. Comparison to Full Proposed Adjustment
The following table compares the financial impact of the IRS's full proposed adjustment to the settlement terms:
The reduction percentage of approximately 89.6% reflects the combined effect of the 87.5% reduction in the income adjustment and the complete elimination of the proposed penalty. When viewed solely in terms of the income adjustment reduction (excluding the penalty component), the reduction is 87.5%. When viewed in terms of the total tax-and-penalty cash exposure, the reduction is approximately 89.6%.
Furthermore, interest savings on the reduced adjustment are substantial. Had the full $380,400,000 adjustment been sustained, estimated underpayment interest would have been in excess of $22,000,000, compared to the approximately $2,840,000 estimated under the settlement. The interest savings therefore provide an additional benefit of approximately $19,000,000 or more, bringing the total savings (tax, penalty, and interest) to well over $100,000,000 as compared to the IRS's full proposed assessment.
V. Impact on FIN 48 / ASC 740-10 Uncertain Tax Position Reserves
The settlement will have a material and favorable impact on PPC's financial statements, specifically with respect to its uncertain tax position reserves maintained under ASC 740-10 (formerly FIN 48).
PPC's pre-settlement FIN 48 reserve for uncertain tax positions related to the Irish IP structure (encompassing both the CSA and legacy royalty arrangements) stood at $62,400,000 as of the most recent reporting period. This reserve reflected PPC's assessment of the probable tax exposure associated with the IRS's examination of the transfer pricing arrangements, including exposure for subsequent tax years that employed the same methodologies and intercompany terms.
Upon execution of the Form 906 Closing Agreement, the $47,600,000 settlement will definitively resolve the uncertain tax positions for Tax Years 2017 through 2020. The settlement amount of $47,600,000 will be treated as the final resolution of the contingent liability for those years, and PPC's reserve will be adjusted accordingly.
The post-settlement reserve is expected to be approximately $14,800,000, reflecting remaining uncertain positions for subsequent tax years (2021 and forward) that are not covered by the settlement and that continue to employ the same transfer pricing methodologies. The reserve for subsequent years will be maintained at a level that reflects PPC's ongoing assessment of the probability and magnitude of potential adjustments in future examination cycles, informed by the outcome of the current examination.
The reserve release of $47,600,000 — net of the $47,600,000 adjustment itself — will impact PPC's income statement. The reduction in the FIN 48 reserve is expected to result in a net benefit to PPC's effective tax rate in Q1 2024. The precise financial statement impact will depend on the timing of the Closing Agreement execution and the applicable accounting period in which the resolution is recognized for financial reporting purposes.
PPC should coordinate with Crestfield & Associates LLP (Martin Ogilvy, Engagement Partner) regarding the appropriate financial statement treatment and disclosures in PPC's Q1 2024 Form 10-Q filing with the Securities and Exchange Commission. Specific considerations include the appropriate period of recognition, the impact on the effective tax rate reconciliation, and the related footnote disclosures regarding the resolution of the contingent tax liability. We are available to participate in those discussions as needed.
VI. Impact on Hargrove National Bank Credit Facility Covenants
PPC's $1.5 billion revolving credit facility with Hargrove National Bank, N.A. (Christine Bellucci, SVP, Relationship Manager) contains covenants that are relevant to the resolution of the IRS examination. Specifically, the credit agreement includes tax-indemnity provisions and material-tax-event covenants that impose reporting obligations and, in certain circumstances, could trigger default provisions in the event of significant adverse tax developments.
Based on our review of the credit agreement and the analysis set forth in our memorandum of November 2023 (addressed to Ms. Staines), the $47,600,000 settlement adjustment does not appear to trigger the material-tax-event default threshold under the credit agreement. The material-tax-event covenant defines a triggering event as a final determination resulting in an additional tax liability exceeding a specified threshold (which, based on the credit agreement's terms, substantially exceeds the $10,000,000 tax liability arising from the settlement). Furthermore, the resolution of the examination through the settlement is favorable from a covenant-compliance perspective, as it eliminates the risk that a substantially larger adverse determination could have implicated the material-adverse-change provisions of the credit agreement.
We recommend that PPC notify Hargrove National Bank of the examination resolution as a matter of good corporate practice and good faith in the lending relationship, even if no formal reporting obligation is triggered. Such notification would demonstrate PPC's transparency and proactive approach to covenant compliance. We further recommend that PPC confirm with its internal legal team and outside banking counsel that no specific reporting obligations under the credit agreement are triggered by the settlement, although our preliminary analysis indicates that they are not.
Had the full proposed $380,400,000 adjustment been sustained, the resulting tax liability of approximately $79,884,000 (plus penalties and interest) would have required careful evaluation under the material-adverse-change provisions of the credit agreement and could potentially have triggered reporting obligations, consent requirements, or — in a worst-case scenario — default provisions. The settlement avoids this risk entirely and provides PPC with certainty regarding its credit facility compliance status.
VII. SEC Disclosure Considerations
The settlement of the IRS examination has implications for PPC's disclosure obligations under the federal securities laws. PPC is a publicly traded company whose shares are listed on the New York Stock Exchange, and PPC is therefore subject to the periodic reporting requirements of the Securities Exchange Act of 1934, including the filing of annual reports on Form 10-K and quarterly reports on Form 10-Q.
PPC previously disclosed the IRS examination and the associated contingent tax liability in its public filings, including in the risk factors section and the income tax footnotes to its consolidated financial statements. The settlement resolves the previously disclosed contingent liability and will require PPC to update its risk factor and contingency disclosures to reflect the resolution. Specifically, PPC should:
(i) Update the income tax footnote disclosure in the Q1 2024 Form 10-Q to reflect the execution of the Closing Agreement, the settlement adjustment amount, the full abatement of penalties, and the reduction in the FIN 48 reserve from $62,400,000 to approximately $14,800,000.
(ii) Update the risk factors section to remove or revise the risk factor relating to the pending IRS examination and to note the favorable resolution of the 2017–2020 examination while disclosing the ongoing risk that similar transfer pricing positions for subsequent tax years may be subject to future IRS examination.
(iii) Disclose the impact of the reserve release on PPC's effective tax rate for the quarter in the management's discussion and analysis ("MD&A") section.
We note that Ridgeview Capital Management LP (Douglas Everett, Managing Partner), PPC's largest institutional shareholder at 8.3% of outstanding shares, has actively monitored PPC's FIN 48 reserve disclosures and has engaged with PPC's investor relations team regarding the IRS examination on multiple occasions. The favorable resolution of the examination, and the associated reduction in the FIN 48 reserve, should positively impact investor perception and may be viewed as a material positive development by the investment community. The reserve release will also improve PPC's reported effective tax rate, which has been a metric of particular interest to institutional investors and sell-side analysts covering PPC.
Deborah Staines, as General Counsel, should coordinate with Crestfield & Associates on the timing and specific content of the disclosure language to ensure compliance with SEC requirements and consistency with PPC's historical disclosure practices. Calderwood & Harkness is available to review draft disclosure language upon request.
VIII. Analysis of Settlement Terms in Light of Hazards of Litigation
This section provides Calderwood & Harkness's assessment of the settlement terms in light of the hazards of litigation — i.e., the risks and uncertainties that PPC would face if it rejected the settlement offer and proceeded to litigation in the United States Tax Court. Appeals Officer Castañeda's settlement offer represents her independent assessment of these hazards, and the analysis below evaluates whether the settlement terms appropriately reflect the relative strengths and weaknesses of the parties' positions on each issue.
A. CSA Cost-Sharing Adjustments
The IRS's proposed CSA cost-sharing adjustments totaled $235,010,000 over the four tax years and were premised on increasing PBI's cost-sharing percentages by 8 to 12 percentage points. The IRS's central contention was that PPC's reasonably anticipated benefit ("RAB") projections systematically understated the value attributable to U.S.-source contributions, thereby resulting in PBI's cost-sharing payments being set too low.
PPC's Position. PPC's cost-sharing ratios of 38.2% to 42.7% were based on rigorous revenue projections that incorporated product-level forecasting, market-by-market analysis, and appropriate discount rates. These projections were developed contemporaneously by PPC's financial planning and analysis team, with input from Crestfield & Associates, and were consistent with the requirements of Treasury Regulation § 1.482-7 for qualified cost-sharing arrangements. The projections reflected the actual commercial dynamics of PPC's and PBI's respective territories, including differing market sizes, pricing environments, regulatory timelines, and competitive conditions.
Economic Support. Whitmore Valuation Group's CPM/TNMM analysis tested PBI's operating margins against a set of 22 comparable independent distributors and IP-holding companies in the pharmaceutical sector. In all four tax years, PBI's operating margins fell within the interquartile range of the comparable set, indicating that PBI's reported income was consistent with arm's-length outcomes. This analysis directly contradicted the IRS's assertion that PBI was retaining excessive profits at PPC's expense.
Litigation Hazard Assessment. Calderwood & Harkness assessed PPC's probability of prevailing on the CSA cost-sharing issue in Tax Court at approximately 65–75%. PPC had a strong factual and economic position, but the CSA methodology involved inherently complex and judgment-intensive analyses regarding reasonably anticipated benefits. The IRS's challenge to the revenue projection methodology — particularly its assertion that PPC's projections failed to account for certain intangible value contributions originating in the U.S. — presented a non-trivial litigation risk, as courts have demonstrated a willingness to scrutinize benefit allocation methodologies and have occasionally adjusted CSA ratios when they found the taxpayer's projections to be insufficiently supported. See, e.g., Altera Corp. v. Commissioner, 145 T.C. 91 (2015), aff'd, 926 F.3d 1061 (9th Cir. 2019); Harborview Corporation, Inc. v. Commissioner, 900 F.3d 610 (8th Cir. 2018).
Settlement Implication. The settlement effectively concedes approximately $20–25 million attributable to CSA issues (estimated, given the blended nature of the resolution), reflecting a modest compromise on the revenue projection methodology while preserving the fundamental validity of PPC's RAB approach and cost-sharing ratios.
B. Legacy IP Royalty Rate
The IRS proposed increasing the legacy IP royalty rate from the contractual 4.5% to 11.0% of net sales, resulting in proposed adjustments of $188,040,000 across the four tax years. The IRS based its proposed rate on its own selection of CUT data from third-party pharmaceutical licensing agreements that purportedly supported a substantially higher arm's-length royalty rate.
PPC's Position. Whitmore Valuation Group identified 14 comparable uncontrolled pharmaceutical license agreements through a rigorous search process using the Vireo Health IT, Recap, and Sundial Health IT databases. The interquartile range of the comparable royalty rates was 3.1% to 6.8%, with a median of 4.4%. PPC's contractual royalty rate of 4.5% falls squarely within the arm's-length range and is virtually identical to the median, providing robust support for the position that the rate was set on arm's-length terms.
Critique of IRS CUTs. The IRS's selected CUTs supporting an 11.0% rate were distinguishable from PPC's intercompany arrangement on multiple comparability grounds. Specifically, the IRS's comparables involved: (i) different therapeutic areas (oncology and rare disease, compared to PPC's immunology and metabolic disorder portfolios), presenting materially different risk and return profiles; (ii) different stages of intellectual property development, including certain early-stage or pre-approval compounds that commanded higher royalty rates due to the greater uncertainty and development costs borne by the licensee; and (iii) different risk allocation structures, including agreements where the licensor bore a substantially greater share of post-licensing development and regulatory costs. These comparability deficiencies rendered the IRS's CUTs unreliable indicators of the arm's-length royalty rate for PPC's intercompany arrangement.
Litigation Hazard Assessment. Calderwood & Harkness assessed PPC's probability of prevailing on the royalty rate issue at approximately 75–85%. PPC's position was very strong, supported by a well-constructed comparable set with appropriate comparability adjustments. The IRS's CUT selection was vulnerable to challenge under the best method rule of Treasury Regulation § 1.482-1(d), which requires that the method selected provide the most reliable measure of an arm's-length result. Courts have consistently emphasized the importance of comparability in CUT analyses and have rejected IRS-proposed adjustments where the comparable transactions differed materially from the controlled transaction. See Harborview Corporation, Inc. v. Commissioner, T.C. Memo. 2016-112 (rejecting the IRS's CUT analysis and adopting a modified version of the taxpayer's method); Guidant LLC v. Commissioner, T.C. Memo. 2021-50.
Settlement Implication. The settlement effectively concedes approximately $15–20 million attributable to royalty issues (estimated), representing a nominal adjustment that implicitly validates the reasonableness of PPC's 4.5% rate while acknowledging some degree of uncertainty inherent in any CUT analysis.
C. Economic Substance / DEMPE Functions
The IRS challenged PBI's economic substance, asserting that key DEMPE functions — those functions relating to the Development, Enhancement, Maintenance, Protection, and Exploitation of the intangible property — remained in the United States and were performed by PPC rather than PBI. If this position were sustained, the consequences would have been severe, as it could have resulted in the recharacterization of substantial portions of PBI's income as U.S.-source income taxable to PPC.
PPC's Position. Calderwood & Harkness's functional analysis comprehensively demonstrated PBI's substantive and independent operations in Ireland. The evidence presented to Appeals included the following:
• Headcount: PBI employed 185 full-time employees as of December 31, 2020, up from 52 employees at the time of the CSA's formation in 2012. These employees included senior management, commercial operations staff, regulatory affairs professionals, medical affairs personnel, finance and accounting staff, and support functions.
• Board Governance: PBI's board of directors held 42 board meetings during the examination period (2017–2020), including regular quarterly meetings and special meetings convened to address strategic decisions such as market entry, pricing, distribution partner selection, and regulatory filings.
• Regulatory Expenditures: PBI incurred cumulative regulatory expenditures of approximately €47,200,000 during the examination period, reflecting PBI's independent engagement with the European Medicines Agency ("EMA") and national regulatory authorities in its operating territories.
• Commercial Independence: PBI independently determined pricing and commercial strategy for 68 country markets outside the Americas, negotiated and executed distribution agreements with local partners, and bore the market risk associated with those operations.
• Physical Presence: PBI maintained approximately 18,000 square feet of office space at Sandyford Business Park, Dublin, Ireland, housing its management team and operational staff.
• Banking: PBI maintained independent banking relationships with Glenmore Bank Ireland plc, separate from PPC's U.S. banking arrangements.
• Leadership: PBI's Managing Director, Aidan Naughton, led the company's commercial decision-making with authority delegated by PBI's board of directors, exercising independent judgment on key business decisions.
Additionally, Calderwood & Harkness (Simmons and Nazari) conducted in-depth interviews with 12 key PBI employees across functional areas, documenting their roles, responsibilities, decision-making authority, and day-to-day activities. These interviews provided compelling first-hand evidence that DEMPE functions with respect to PBI's territories were genuinely performed in Ireland and were not mere ministerial or administrative activities directed from the United States.
Litigation Hazard Assessment. Calderwood & Harkness assessed PPC's probability of prevailing on the economic substance issue at approximately 85–90%. This was the strongest element of PPC's case. The factual record demonstrating PBI's independent operations, significant employee base, regulatory engagement, and commercial decision-making was robust and well-documented. The IRS's economic substance argument was largely conclusory and did not adequately address the substantial evidence of PBI's operational independence. While economic substance challenges have succeeded in egregious cases involving shell entities with minimal operations, PBI's profile was far removed from such cases. Courts have upheld the substance of foreign entities where the entity maintained meaningful operations and personnel, exercised independent judgment, and bore genuine economic risks. See Granite Harbor Partners LLC v. Commissioner, T.C. Memo. 2017-147 (evaluating functional substance of related entities in transfer pricing context).
Settlement Implication. The settlement's modest total adjustment of $47,600,000 (12.51% of proposed adjustments) implicitly reflects Appeals' acknowledgment that PBI's economic substance was well-established and that the IRS's economic substance challenge was unlikely to be sustained. Had Appeals given significant weight to the economic substance argument, the settlement amount would have been substantially higher.
D. PCT Valuation
Although the PCT itself was consummated in 2012 — a year outside the examination period — the IRS used its own PCT valuation as an evidentiary tool to support its CSA and royalty adjustments for the 2017–2020 tax years. The IRS valued the PCT at $852 million, compared to PPC's original PCT valuation of $312 million, contending that the disparity indicated that PPC had transferred excessive value to PBI at the inception of the CSA.
PPC's Position. Whitmore's discounted cash flow ("DCF") analysis of the PCT, employing a weighted average cost of capital ("WACC") of 9.8% reflecting pharmaceutical-industry risk premiums, yielded a PCT valuation range of $278 million to $361 million. PPC's original PCT payment of $312 million fell within this range, supporting the conclusion that the PCT was priced on arm's-length terms.
Critique of IRS Valuation. The IRS's PCT valuation of $852 million was based on a WACC of 7.2%, which was inappropriately low given the risk profile of pharmaceutical intellectual property. The IRS's discount rate failed to account for the substantial development risk, regulatory risk, and commercial uncertainty associated with pharmaceutical intangibles — risks that the academic literature and market data consistently indicate warrant risk premiums above those reflected in a 7.2% discount rate. Whitmore's detailed WACC computation, supported by pharmaceutical-industry beta data, equity risk premiums, and small-firm premiums from Ridgeline Consulting Group and Ashbury Technologies data, demonstrated that a WACC in the range of 9.0% to 10.5% was appropriate for the subject intangible property.
Settlement Implication. Critically, the settlement does not require PPC to make any concession on the PCT valuation itself. The $312 million PCT payment remains intact and unchallenged. This is a significant outcome because any concession on the PCT valuation would have had cascading implications for PPC's cost-sharing computations and intangible property allocations in subsequent tax years beyond the examination period. The preservation of the original PCT valuation protects PPC's transfer pricing architecture for years to come.
E. Overall Assessment
The settlement rate of 12.51% ($47,600,000 of $380,400,000) is consistent with Calderwood & Harkness's pre-Appeals target of 10–15% of proposed adjustments. This target was established based on our comprehensive assessment of the relative strengths and weaknesses of PPC's positions on each issue, the quality and persuasiveness of the economic analyses prepared by Whitmore, the strength of the economic substance evidence, and our experience with IRS Appeals outcomes in comparable transfer pricing cases.
The settlement result falls well within the settlement authority parameters that were approved by PPC management prior to the Appeals conference:
• Target range: 10–15% of proposed adjustments ($38,040,000 – $57,060,000)
• Hard ceiling: 20% of proposed adjustments ($76,080,000)
• Achieved: 12.51% ($47,600,000)
The favorable outcome reflects the strength of PPC's factual position — particularly the compelling evidence of PBI's economic substance — the quality of the economic analyses prepared by Whitmore Valuation Group, the comprehensive contemporaneous transfer pricing documentation maintained by PPC, and the effective advocacy by the Calderwood & Harkness team throughout the examination and Appeals process. It also reflects Appeals Officer Castañeda's careful and thorough evaluation of the hazards of litigation, which we believe correctly weighted the significant risks the IRS would have faced in sustaining its proposed adjustments before the Tax Court.
IX. Penalty Abatement Analysis
The full abatement of the proposed IRC § 6662(e) substantial valuation misstatement penalty represents a significant and independently valuable component of the settlement outcome. The proposed penalty of $15,977,000 would have been assessed at the 20% rate on any tax attributable to a net IRC § 482 transfer pricing adjustment, regardless of the ultimate settlement amount of the underlying income adjustment. That is, even at the settlement-level adjustment of $47,600,000, a penalty could theoretically have been imposed on the tax attributable to that adjustment (approximately $2,000,000 in penalties on the settlement adjustment amount) had PPC not established a defense to penalties. The full abatement therefore eliminates penalty exposure entirely.
Appeals Officer Castañeda accepted PPC's reasonable-cause defense on two independent grounds:
First, PPC maintained contemporaneous transfer pricing documentation for each of the four tax years under examination, prepared by Crestfield & Associates LLP (Susan Lam, Transfer Pricing Partner). This documentation was prepared at or before the time each return was filed and met the substantive and procedural requirements of IRC § 6662(e)(3)(B) and the regulations thereunder. The documentation included a detailed functional analysis of PPC's and PBI's respective roles, risks, and contributions; a description and application of the transfer pricing methods selected; a comparability analysis; and financial data supporting the arm's-length nature of the intercompany transactions. The existence of this documentation created a rebuttable presumption that PPC had reasonable cause for its transfer pricing positions.
Second, PPC demonstrated reasonable cause through its reliance on qualified advisors. Specifically, PPC engaged Crestfield & Associates LLP for the original transfer pricing documentation and compliance work, and subsequently engaged Calderwood & Harkness LLP and Whitmore Valuation Group LLC for the defense of its positions. PPC's reliance on these qualified professionals — each with recognized expertise in transfer pricing matters — further supported the conclusion that PPC acted with reasonable cause and in good faith in determining its transfer pricing positions.
The penalty abatement eliminates the 20% penalty that would have applied to any tax attributable to a net IRC § 482 adjustment for the 2017–2020 tax years, regardless of the settlement adjustment amount. It also resolves the IRS's reserved (but unasserted) IRC § 6662(h) gross valuation misstatement penalty at the 40% rate, eliminating any residual risk that a higher penalty could have been imposed.
The penalty outcome underscores the critical importance of maintaining robust contemporaneous transfer pricing documentation, a practice that Calderwood & Harkness strongly recommends PPC continue for all current and future tax years.
X. Potential Irish Tax Implications
The settlement of the U.S. examination raises potential Irish tax implications that require coordination with PPC's Irish tax counsel, Thornbury & Keogh (Ciarán Thornbury, Lead Partner).
The $47,600,000 U.S. income adjustment has the potential to create a corresponding adjustment on PBI's Irish tax return. Under the U.S.-Ireland Income Tax Treaty, Article 9 (Associated Enterprises), where one Contracting State (the United States) makes an adjustment to the profits of an enterprise of that State in respect of transactions with an associated enterprise of the other Contracting State (Ireland), the other State is generally required to make a corresponding adjustment to the amount of tax charged on the associated enterprise, to the extent necessary to eliminate double taxation.
If PBI's Irish taxable income is not correspondingly reduced to reflect the $47,600,000 U.S. adjustment, PPC and PBI would effectively be subject to double taxation on the same income. To avoid this result, PPC has the option of requesting relief through the Mutual Agreement Procedure ("MAP") provided under Article 25 of the U.S.-Ireland Income Tax Treaty. A MAP request would invoke the competent authorities of the United States (the IRS) and Ireland (the Revenue Commissioners) to consult with one another to resolve the double taxation issue.
However, the decision to pursue a MAP request involves a cost-benefit analysis. MAP proceedings can be time-consuming (often requiring 18 to 36 months to resolve) and involve additional professional fees. Given the relatively modest settlement amount of $47,600,000 and the resulting Irish tax implications (which would be computed at Ireland's 12.5% corporate tax rate or, for qualifying income, the 6.25% Knowledge Development box rate), the potential Irish tax relief may be in the range of approximately $3,000,000 to $6,000,000. PPC should evaluate whether the magnitude of potential relief justifies the cost and administrative burden of pursuing MAP.
Additionally, PPC should consider the impact of the U.S. settlement on PBI's Knowledge Development box ("KDB") claims. PBI has claimed the reduced 6.25% effective tax rate under the KDB regime for qualifying income derived from qualifying patents and other qualifying intellectual property. If the U.S. adjustment is characterized as reducing PBI's qualifying income, the KDB benefit could be affected. This issue requires further analysis by Thornbury & Keogh in light of the specific settlement terms and the applicable Irish tax provisions.
Leila Nazari of Calderwood & Harkness has been coordinating with Thornbury & Keogh on these issues and has exchanged correspondence with Mr. Thornbury dated March 20, 2024, outlining the settlement terms and requesting a preliminary assessment of the Irish tax consequences. We expect to receive Thornbury & Keogh's analysis in the coming weeks and will share it with PPC management upon receipt.
XI. State Tax Implications
The $47,600,000 federal income adjustment resulting from the settlement will flow through to PPC's state income tax returns in PPC's filing jurisdictions. PPC files income tax returns in multiple states, including its state of incorporation and principal place of business, New Jersey, as well as other states in which PPC has nexus.
The state-level additional tax exposure resulting from the federal settlement will depend on several factors, including:
(i) Each state's conformity (or non-conformity) to the federal IRC § 482 adjustment;
(ii) PPC's apportionment factors (sales, payroll, and property) in each filing jurisdiction, which determine the portion of the federal income adjustment that is apportioned to each state;
(iii) Each state's corporate income tax rate;
(iv) Whether PPC files on a separate-company, combined, or consolidated basis in each jurisdiction; and
(v) Whether any state-level penalties or interest provisions are triggered by the amended federal return.
A detailed state tax impact analysis is currently being prepared and will be provided to PPC under separate cover. Leila Nazari is leading this analysis and will coordinate with PPC's state tax team to ensure that the amended state returns are filed in a timely manner following the execution of the Closing Agreement and the filing of the federal amended returns. We anticipate that the aggregate state tax exposure will be modest relative to the federal exposure, but the precise amounts will depend on the apportionment analysis.
XII. Recommendation
A. Acceptance of Settlement Offer